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Introduction
Peroxisome proliferator-activated receptor-γ coactivator-
1α (PGC-1α) is a transcriptional coactivator and master regu-
lator of genes involved in oxidative metabolism and mitochon-
drial biogenesis that controls cellular responses to metabolic 
demands inducing genes that coordinately increase the oxida-
tive capacity of the cell, including mitochondrial biogenesis and 
energy metabolism genes (1). Enhanced oxidative phosphoryla-
tion is normally associated with increased mitochondrial reac-
tive oxygen species (ROS) production, and this negative effect 
is amply compensated by PGC-1α induction of antioxidant sys-
tems, resulting in a net reduction of cellular ROS levels when 
PGC-1α is active (2). Thereby, PGC-1α has been shown to play a 
fundamental role in metabolic control as well as in the terminal 
differentiation of high-energy metabolism tissues including the 
myocardium (3, 4).
Constitutive PGC-1α expression levels are likely to reflect 
the general metabolic status of patients, with high levels pre-
sumably associated with a higher level of oxidative metabolism, 
high oxygen consumption rates, and reduced general oxidative 
stress, while low basal PGC-1α levels are expected to be associ-
ated with enhanced reliance on glycolytic metabolism, low oxy-
gen consumption, and elevated ROS levels. This last condition 
tended to be more frequent in diabetic patients, as previously re-
ported (5). Importantly, low PGC-1α levels may also be the cause 
of the high levels of ROS and poor tolerance to ischemic injury 
generally associated with those patients (6, 7).
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prevalence of some metabolic disorders.
Methods: This was a cohort of 35 consecutive stable heart failure patients with severe aortic stenosis who underwent an elective aortic valve 
replacement surgery. mRNA PGC-1α expression was simultaneously determined from myocardial biopsy specimens and blood samples ob-
tained during surgery by quantitative PCR, and a correlation between samples was made using the Kappa index. Patients were divided into two 
groups according to the detection of baseline expression levels of PGC-1α in blood samples, and comparisons between both groups were made 
by chi-square test or unpaired Student’s t-test as appropriate.
Results: Based on myocardial biopsies, we found that mRNA PGC-1α expression in blood samples showed a statistically significant correlation 
with myocardial expression (Kappa index 0.66, p<0.001). The presence of higher systemic PGC-1α expression was associated with a greater 
expression of some target genes such as silent information regulator 2 homolog-1 (x-fold expression in blood samples: 4.43±5.22 vs. 1.09±0.14, 
p=0.044) and better antioxidant status in these patients (concentration of Trolox: 0.40±0.05 vs. 0.34±0.65, p=0.006). 
Conclusions: Most patients with higher peripheral expression also had increased myocardial expression, so we conclude that the non-invasive 
estimation of mRNA PGC-1α expression from blood samples provides a good approach of the constitutive status of the mitochondrial protection 
system regulated by PGC-1α and that this could be used as prognostic indicator in cardiovascular disease. (Anatol J Cardiol 2016; 16(0): 000-00)
Key words: peroxisome proliferator-activated receptor-γ coactivator-1α, mRNA expression, cardiac surgery, prognosis marker
ABSTRACT
Fabregat-Andres et al.
mRNA PGC-1α levels
Anatol J Cardiol 2016; 16(0): 000-000
DOI:10.5152/AnatolJCardiol.2015.6466
In this regard, PGC-1α has been proposed to play a protec-
tive role in mouse models of cardiac ischemia and heart fail-
ure (8, 9), so it is suggested that PGC-1α levels are relevant as 
prognostic marker in patients with cardiovascular disease. Be-
cause the direct analysis of PGC-1α expression in the heart is 
not possible in clinical practice, we previously performed test-
ing in acute myocardial infarction patients to determine whether 
PGC-1α activity in peripheral blood samples could be analyzed, 
and we found that the estimation of peripheral PGC-1α expres-
sion was feasible (10) and that its induction correlated with the 
extent of myocardial necrosis and left ventricular remodeling in 
ST-segment elevation myocardial infarction patients (11).
Nonetheless, if PGC-1α expression in blood samples is corre-
lated to myocardial expression has not been previously evaluated, 
it would be imperative to provide value to these previous clinical 
studies. Therefore, in this study, we simultaneously analyzed the 
expression of PGC-1α in myocardial biopsies and peripheral blood 
in patients undergoing cardiac surgery and correlated it with the 
expression of superoxide dismutase 2 (SOD2), a target gene within 
the mitochondrial system of oxidative stress protection. The myo-
cardial and peripheral mRNA expressions of both AMP-activated 
protein kinase (AMPK) and silent information regulator 2 homolog 
1 (SIRT-1) were also analyzed as key regulators of PGC-1α activity. 
AMPK and SIRT-1 are two metabolic sensors that could directly 
affect PGC-1α activity through post-transcriptional modifica-
tions (12). Thus, phosphorylation by AMPK results in an increase 
in PGC-1α protein levels as a consequence of increased protein 
stability, and deacetylation via SIRT-1 keeps PGC-1α in an active 
state. Taken together, these players constitute an energy-sensing 
axis that controls metabolic homeostasis, and the abnormal func-
tion of this network could be essential in the pathophysiology of 
type 2 diabetes and other metabolic disorders (13).
In addition, total antioxidant status and autophagy markers 
were analyzed as indicators of comorbidity and advanced dis-
ease. Autophagy is the process for degrading and recycling long-
lived proteins and cytoplasmic organelles through the lysosome, 
which plays an important role in cardiac remodeling, aging, and 
inflammation to maintain cellular homeostasis in the heart. In this 
regard, some stressors such as hypoxia could induce autophagy 
that protects against ischemia-reperfusion injury (14, 15); it is sug-
gested that autophagy plays a key role in mediating the regres-
sion of cardiac hypertrophy during mechanical unloading (16, 17).
Therefore, the aim of the study was to determine if the myo-
cardial and peripheral expressions of PGC-1α and its target 
genes are well correlated and to analyze the variability of PGC-1α 
expression depending on the pro-inflammatory status of patients 
and prevalence of some metabolic diseases such as diabetes.
Methods
Study population
This is a cohort of 35 consecutive patients electively referred 
to our Department of Cardiac Surgery (Cardiovascular Institute 
from General University Hospital, Valencia, Spain) to undergo 
aortic valve replacement surgery between June and December 
2014. Inclusion criteria were as follows: severe aortic valve dis-
ease indicating replacement surgery, with or without concomi-
tant coronary heart disease; no episodes of acute decompen-
sated heart failure or acute coronary syndrome in the previous 
3 months; and age of >18 years with a capacity to sign the in-
formed consent form. Were selected stable patients with aor-
tic valve disease to homogenize both the study population with 
respect to clinical and surgical characteristics as the protocol to 
obtain the cardiac biopsies?
Clinical and biochemical data
Clinical data collected included medical history with cardio-
vascular risk factors and medications and baseline biochemical 
values such as glucose, hemoglobin, and creatinine levels. The 
parameters analyzed to characterize immune response were as 
follows: leukocyte count prior to surgery and 48 h later (includ-
ing total neutrophil, lymphocyte, and monocyte counts and their 
relative percentages); baseline, 24 h, and 48 h C-reactive protein 
(CRP) levels; and baseline, 8 h, 24 h, and 48 h lactate levels. As 
indirect marker of myocardial necrosis was used the maximum 
value of troponin I during admission.
Echocardiography
Transthoracic echocardiogram was performed in all pa-
tients as local protocol. Left ventricular ejection fraction, left 
ventricular end-diastolic and end-systolic diameters, tricuspid 
annular plane systolic excursion, and systolic pulmonary artery 
pressure through a tricuspid regurgitate jet were measured be-
fore surgery.
Variable of cardiac surgery 
All patients underwent aortic valve replacement through me-
dial sternotomy. Those patients with concomitant coronary ar-
tery disease underwent coronary bypass surgery in the same in-
tervention. The total time of extracorporeal circulation and time 
of myocardial ischemia were recorded, as well as the number of 
coronary artery bypass grafts, where appropriate.
Acquisition of myocardial biopsies
Endomyocardial biopsies were obtained during aortic valve 
replacement. Briefly, after on-pump cannulation and aortic 
cross-clamping, the heart was arrested using a cold cardiople-
gia solution. Endoventricular access was performed through a 
10–15-mm oblique aortotomy above the sinotubular junction, and 
endomyocardial specimens were excised from the left ventricu-
lar basal septum using a cold scalpel No. 11.
Preparation of mononuclear cells from blood samples
Immediately before starting extracorporeal circulation, 6–8 
mL of peripheral blood collected in EDTA vacutainers (BD) were 
used to isolate mononuclear cells by Ficoll density gradient cen-
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trifugation using Ficoll-Paque™ (Miltenyi Biotec, Surrey, United 
Kingdom), following the manufacturer’s instructions. Isolated 
cells were analyzed using Cytospin and Fast Panoptic Staining 
(Panreac, Barcelona, Spain). Only preparations containing ≥90% 
mononuclear cells were used for the analysis.
Real-time quantitative PCR
Total RNA was isolated using Trizol™ (Invitrogen), follow-
ing the manufacturer’s instructions. The quality of RNA was 
evaluated in a bioanalyzer and quantitated in a nanodrop. RNA 
used had a ratio of absorbance at 260 nm and 280 nm of ≥1.8 
and an RNA integrity number of ≥8. Relative mRNA expression 
levels of PGC-1α, SOD2, AMPK, and SIRT-1 were determined 
by quantitative PCR of retrotranscribed cDNA with specific 
primers as previously described (18), both for peripheral blood 
samples and cardiac biopsies. Results were expressed as x-
fold expression over the minimum value detected among all 
patients. 
Antioxidant assay kit
The total antioxidant status of the patients was estimated 
using a Trolox™ Equivalent Antioxidant Capacity assay (Sigma-
Aldrich, St. Louis, USA) in plasma samples based on the scav-
enging of the 2,2′-azino-bis-(3-ethylbenzothiazoline-6-sulfonic 
acid) (ABTS) radical (ABTS•), a soluble chromogen that is con-
verted into a colorless product when it reacts with the ferryl 
myoglobin radical (a product from the reaction between met-
myoglobin and hydrogen peroxide). The concentration of Trolox, 
a water-soluble vitamin E analog, was used in analyses as the 
antioxidant control.
Ethics
The experimental protocol was approved by the Local Ethical 
Committees: Research Foundation and Cardiovascular Institute 
from University General Hospital of Valencia. All patients signed 
a written informed consent form, and all procedures conformed 
to the Declaration of Helsinki.
Statistics
Categorical values were expressed as absolute numbers and 
percentages and continuous variables as mean±standard devia-
tion. The Kolmogorov–Smirnov test was used to test the normal-
ity of the distribution. Patients were divided in two groups ac-
cording to the detection of baseline expression levels of PGC-1α 
in blood samples, assuming a two-fold expression over the mini-
mum value detected as the cut-off value. Comparisons between 
both groups were made by the chi-square test or unpaired Stu-
dent’s t-test as appropriate. The correlation between periph-
eral and cardiac samples was made using the Kappa index. All 
p-values refer to two-tailed tests of significance and p-values 
of <0.05 were considered to be significant. Statistical analyses 
were performed using SPSS for Windows, release 19.0 (SPSS 
Inc., Chicago, IL). 
Results 
Baseline patient characteristics 
The general characteristics of the patients are presented 
in Table 1. The patients were divided in two groups according 
to the detection of the baseline expression levels of PGC-1α 
in blood samples. Both groups were comparable with respect 
to cardiovascular risk factors, medication, laboratory and 
echocardiographic parameters, and heart failure functional 
class, with a trend toward a higher prevalence of diabetic 
patients in the group with a lower baseline expression of 
PGC-1α.
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Table 1. Baseline patient characteristics according to the expression 
of PGC-1α in blood samples
  All Patients Patients P 
  patients with with 
  (n=35) PGC-1α PGC-1α 
   expression >2 expression <2 
   -fold (n=11) -fold (n=24)
Age, years 69.8±11.9 63.3±15.7 72.6±8.8 0.10
Male, n (%) 19 (54) 7 (64) 12 (50) 0.22
Cardiovascular risk factors, n (%)
Hypertension 29 (83) 9 (82) 20 (83) 0.91
Diabetes 9 (26) 1 (9) 8 (33) 0.13
Dyslipidemia 22 (63) 6 (55) 16 (67) 0.50
Smoking history 18 (51) 7 (64) 11 (46) 0.34
Medication, n (%)
ACEI or ARB 23 (66) 7 (64) 16 (67) 0.52
Diuretics 24 (69) 6 (55) 18 (75) 0.24
Beta-blockers 14 (40) 7 (64) 7 (29) 0.07
Estatins 20 (57) 6 (55) 14 (58) 0.84
Metformin 6 (17) 1 (9) 5 (21) 0.14
ODM 3 (9) 1 (9) 2 (9) 0.92
Insulin 4 (12) 0 (0) 4 (18) 0.14
Laboratory
Hemoglobin, g/dL 13.1±1.1 13.4±1.2 12.9±1.1 0.15
Creatinine, mg/dL 0.8±0.2 0.9±0.2 0.8±0.3 0.62
Hb1Ac (%) 6.2±0.6 6.0±0.9 6.6±0.5 0.36
Echocardiography
LVEF (%) 60.4±10.3 59.4±14.2 60.9±8.2 0.72
LVEDD, mm 48.8±9.4 51.6±10.9 47.5±8.5 0.20
LVESD, mm 30.7±9.0 33.9±10.5 29.1±8.0 0.23
TAPSE, mm 22.7±6.0 24.0±4.7 22.1±6.6 0.40
sPAP, mm Hg 39.1±9.9 35.5±8.2 40.8±10.3 0.11
Coronarography
CAD, n (%) 8 (23) 5 (45) 3 (13) 0.03
VSS 0.2±0.6 0.4±0.9 0.2±0.5 0.41
History of heart failure
NYHA functional class 2.7±0.5 2.6±0.5 2.7±0.5 0.87
ACEI - angiotensin-converting enzyme inhibitor; ARB - angiotensin II receptor blocker; 
CAD - coronary artery disease; LVEDD - left ventricular end-diastolic diameter; LVESD 
- left ventricular end-diastolic end-systolic diameter; LVEF - left ventricular ejection 
fraction; ODM - other oral an diabetic medication; sPAP - systolic pulmonary artery 
pressure; TAPSE - tricuspid annular plane systolic excursion; VSS - No of vessels with 
significant stenosis. Comparisons between both groups were made by chi-square and 
unpaired Student’s t-tests. Quantitative data expressed as mean±standard deviation. 
Significant if p<0.05
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When coronarography results were analyzed, a significantly 
higher prevalence of coronary artery disease was found in pa-
tients with a higher constitutive expression of PGC-1α. Nonethe-
less, if we compare cardiac surgery variables, such as time of isch-
emia or peak of troponin monitored after surgery, depending on 
this condition, no significant differences were detected (Table 2).
Correlation between mononuclear 
cell and myocardial expressions
When a scatter plot with both variables was generated, we 
found a large dispersion of values, consistent with the variabil-
ity of PGC-1α expression in clinical studies (Fig. 1). Therefore, 
to establish if peripheral and myocardial expressions of PGC-1α 
were indeed correlated, a cross table with both expressions was 
constructed classifying patients according to the cut-off value 
of 2-fold expression level, as described previously. With this, we 
observed a good correlation between both expressions with a 
kappa index of 0.66 (p<0.001); 8 of the 11 patients with higher pe-
ripheral expression also had increased myocardial expression. 
PGC-1α target genes and regulators
To evaluate if peripheral PGC-1α expression correlated with 
the expression of target genes, SOD2 expression was determined 
both in blood samples and myocardial biopsy specimens. We 
found that SOD2 mRNA levels were slightly increased in patients 
with higher peripheral PGC-1α expression, although this was only 
in myocardial biopsy specimens, and differences were not statis-
tically significant (x-fold: 2.01±3.21 vs. 1.03±0.03, p=0.14) (Fig. 2). 
To assess if post-transcriptional regulators that have been 
shown to increase the activity of PGC-1α were differently ex-
pressed in both groups according to peripheral PGC-1α expres-
sion, we determined AMPK and SIRT-1 mRNA levels both in blood 
samples and myocardial biopsy specimens. We found that in pa-
tients with a higher peripheral PGC-1α expression, SIRT-1 mRNA 
expression was increased both in blood samples and myocardial 
biopsy specimens, although only in the first reached significance 
(x-fold: 4.43±5.22 vs. 1.09±0.14, p=0.044 in blood samples; and 
2.16±3.29 vs. 1.03±0.03, p=0.096 in myocardial biopsy specimens) 
(Fig. 2). No differences were found in AMPK expression.
Autophagy and total antioxidant status 
As a marker of autophagy, we analyzed the expression of 
microtubule-associated protein-1 light chain-3 (MAP1LC3), 
which is involved in the elongation of the membrane of autopha-
gosomes, in both groups. We found that the expression of MA-
P1LC3 transcripts was mildly increased in the myocardial biopsy 
specimens of patients with a higher peripheral PGC-1α expres-
sion, although differences were not significant (x-fold: 2.34±3.97 
vs. 1.03±0.19, p=0.11) (Fig. 2). 
When we determine the total antioxidant status as an indirect 
marker of pro-inflammatory condition of the patients in both groups, 
we observed that those with a greater peripheral PGC-1α expres-
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Figure 1. Comparative mRNA expression of PGC-1α in blood samples 
and myocardial biopsy specimens
Patients were divided according to the cut-off value of 2-fold PGC-1α expression in blood 
samples (i.e., patients with a significant higher expression: >2-fold expression and patients 
without detectable PGC-1α expression: <2-fold expression). Kappa index was used as 
measure of agreement between both determinations
Table 2. Cardiac surgery variables according to the expression of 
PGC-1α in blood samples
  All Patients Patients P 
  patients with with 
  (n=35) peripheral peripheral 
   PGC-1α PGC-1α 
   expression >2 expression <2 
   -fold (n=11) -fold (n=24)
Echocardiographic presurgical gradients, mm Hg
Peak aortic gradient 81.3±24.0 77.0±31.6 82.9±21.6 0.61
Mean aortic gradient 44.6±16.5 41.6±21.3 45.8±14.8 0.57
Extracorporeal circulation
Ischemia times, min 104.5±35.9 111.7±41.2 100.9±33.6 0.47
Coronary artery bypass grafting
Concomitant BS 5 (14) 3 (27) 2 (8) 0.65
Total coronary bypass 9 5 4 0.83
Myocardial necrosis related to surgery
Peak of troponin, ng/mL 1.4±2.6 1.7±2.7 1.2±2.6 0.59
Comparisons between both groups were made by chi-square and unpaired Student’s 
t-tests. Quantitative data expressed as mean±standard deviation. Significant if p<0.05. 
BS - bypass surgery
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sion had a higher concentration of Trolox (0.40±0.05 vs. 0.34±0.65, 
p=0.006), suggesting higher oxidative metabolism levels, high oxy-
gen consumption rates, and reduced general oxidative stress.
Immune response 
To characterize the immune response triggered by surgery, 
absolute and relative leukocyte counts and CRP and lactate 
levels were monitored after cardiac intervention (Table 3A). We 
found that patients with a greater baseline PGC-1α expression 
in blood samples had a higher absolute monocyte count before 
surgery (0.68±0.16 vs. 0.55±0.11, p=0.01) and a trend toward a 
high absolute neutrophil count, without other significant differ-
ences in absolute and relative leukocyte counts. With respect 
to lactate levels, which are increased with anaerobic glycoly-
sis, we found that patients with a higher expression of PGC-1α 
showed lower levels at 8 h after surgery, suggesting more reli-
ance on oxidative metabolism. We found similar differences at 
24 h, although these were not significant. Finally, regarding CRP 
levels, an inflammatory unspecific marker, we observed that pa-
tients with a high PGC-1α expression had significant lower lev-
els before surgery (0.21±0.11 vs. 0.50±0.42, p=0.01), suggesting a 
less inflammatory burden in these patients.
To better compare the individual response to surgery, we an-
alyzed percentage changes between the groups and found that 
patients with a lower PGC-1α expression showed a greater per-
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  Patients with Patients with P value 
  peripheral peripheral  
  PGC-1α d PGC-1α  
  expression expression 
   >2-fol <2 fold 
  n=11 n=24
Peripheral expression (x-fold)
 PGC-1α 4.14 (±3.01) 1.17 (±0.30) <0.001
 SOD2 1.12 (±0.33) 1.04 (±0.04) 0.22
 AMPK 1.04 (±0.03) 1.08 (±0.20) 0.33
 SIRT1 4.43 (±5.22) 1.09 (±0.14) 0.044
 MAP1LC3 1.04 (±3.0) 1.00 (±0.0) 0.10
Myocardial expression (x-fold)
 PGC-1α 5.27 (±5.22) 1.21 (±0.33) 0.001
 SOD2 2.01 (±3.21) 1.03 (±0.03) 0.14
 AMPK 2.03 (±3.97) 1.03 (±0.02) 0.13
 SIRT1 2.16 (±3.29) 1.03 (±0.03) 0.096
 MAP1LC3 2.34 (±3.97) 1.03 (±0.19) 0.11
Total antioxidant status
 Trolox (mM) 0.40 (±0.05) 0.34 (±0.65) 0.006
Figure 2. Relative mRNA expression of target genes and total 
antioxidant status according to PGC-1α expression in blood samples.
mRNA expression is represented as x -fold expression over the minimum expression 
detected among all patients. SOD2-superoxide dismutase 2. AMPK-AMP-activated protein 
kinase. SIRT-1-silent information regulator 2 homolog 1. MAP1LC3-microtubule-associated 
protein-1 light chain-3. Trolox: 6-hidroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid
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Table 3. Immune response triggered by cardiac surgery: leukocyte 
counts and C-reactive protein and lactate levels according to 
peripheral PGC-1α expression
 Patients with  Patients with P 
 peripheral PGC-1α  peripheral PGC-1α 
 expression >2 fold expression <2 fold 
 (n=11) (n=24)
A
Leukocytes
Absolute counts (·109/L)
Neutrophils at baseline 7.41 (±2.30) 5.51 (±2.78) 0.06
Neutrophils 48 h 14.34 (±3.96) 13.45 (±4.14) 0.55
Lymphocytes at baseline 1.94 (±0.66) 1.78 (±0.67) 0.52
Lymphocytes 48 h 1.01 (±0.53) 0.81 (±0.44) 0.26
Monocytes at baseline 0.68 (±0.16) 0.55 (±0.11) 0.01
Monocytes 48 h 1.09 (±0.53) 0.94 (±0.33) 0.33
Relative counts, (%)
Neutrophils at baseline 67.1 (±9.5) 65.7 (±10.7) 0.71
Neutrophils 48 h 85.7 (±5.4) 88.1 (±3.1) 0.10
Lymphocytes at baseline 22.5 (±8.3) 23.7 (±9.6) 0.72
Lymphocytes 48 h 6.9 (±4.4) 5.4 (±2.2) 0.19
Monocytes at baseline 7.5 (±1.3) 7.1 (±1.9) 0.53
Monocytes 48 h 6.7 (±3.0) 6.3 (±1.7) 0.61
Lactate, mmol/L
8 h after surgery 1.45 (±0.91) 2.81 (±1.53) 0.002
24 h after surgery 2.11 (±0.92) 2.74 (±1.11) 0.09
48 h after surgery 2.02 (±1.12) 1.92 (±0.86) 0.80
C-reactive protein, mg/dL
Before surgery 0.21 (±0.11) 0.50 (±0.42) 0.037
24 h after surgery 9.06 (±4.93) 7.59 (±3.36) 0.31
48 h after surgery 1.24 (±4.17) 1.41 (±6.11) 0.39
B
Leukocytes
Percentage changes (%)
Neutrophil 48 h − 0 h/0 h 104.3 (±63.3) 167.7 (±93.0) 0.026
Lymphocyte 48 h − 0 h/0 h -41.9 (±35.7) -38.8 (±85.8) 0.88
Monocyte 48 h − 0 h/0 h 65.1 (±78.6) 78.5 (±82.5) 0.65
Comparisons between both groups were made by unpaired Student’s t-test. Quantitative 
data expressed as mean±standard deviation. Percentage changes indicate the percent-
age difference between the value at baseline and the value at 48 h. Significant if p<0.05
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centage increase in the absolute neutrophil count at 48 h, with 
no other significant differences (Table 3B).
PGC-1α expression in metabolic disorders
As shown in Figure 1, only 1 of the 9 diabetic patients in our 
population showed elevated expression of PGC-1α both in blood 
samples and myocardial biopsy specimens. When we also con-
sidered those patients with glycated hemoglobin of ≥6.5%, which 
is cut-off value recommended for diagnosing diabetes according 
current guidelines (19), we found similar significant distributions 
(Table 4). This downregulation in PGC-1α mRNA expression ob-
served in patients with metabolic disorders, assuming both with 
previous diagnosis of diabetes and those with glycated hemo-
globin of ≥6.5%, correlated with lower transcripts of SIRT-1 and 
SOD2, although the latter was not significant (Fig. 3). No signifi-
cant differences were reached in the total antioxidant status and 
autophagy markers.
Discussion
This study shows that PGC-1α mRNA levels in blood samples 
are well correlated with myocardial expression for the first time 
and could thus be reliable to estimate the constitutive expres-
sion of PGC-1α and monitor changes in different clinical settings. 
Our previous studies (10, 11) performed in acute myocar-
dial infarction patients showed that the peripheral estimation 
of PGC-1α expression was feasible and that patients could 
be classified in two alternative ways based on PGC-1α lev-
els: those with significant detectable levels of PGC-1α mRNA 
and those without detectable constitutive expression. The first 
study showed that infarct size positively correlated with the in-
duction of PGC-1α expression after acute coronary syndrome. 
The second study supported those notions and found that both 
low basal PGC-1α levels and induction correlated with larger 
necrotic areas after myocardial infarction. To validate these 
results, we conducted the present study in cardiac surgery pa-
tients and suggested a good correlation between both expres-
sion levels.
Because the expression of PGC-1α considerably varies in clini-
cal studies, unlike experimental studies where the control of cer-
tain variables is ensured, we divided patients into two groups ac-
cording to the detectable expression, establishing a cut-off value of 
2-fold expression over the minimum detected value among patients. 
This method of analysis of PGC-1α mRNA expression facilitates 
the classification of patients and easily allows the assessment of 
the clinical significance of results. To our knowledge, all previous 
clinical studies used biopsy specimens to determine PGC-1α mRNA 
expression both with myocardial (20) and skeletal muscle biopsy 
specimens (21, 22), the most commonly used. Our protocol estimat-
ing peripheral PGC-1α expression could provide a rough overview 
of the systemic activation of this coactivator and its target genes 
without using invasive or overly sophisticated techniques.
The constitutive higher expression of PGC-1α has been 
shown to be related to the upregulation of mitochondrial bio-
Table 4. PGC-1α expression in blood samples and myocardial biopsy 
specimens according to the presence of metabolic disorders
  PGC-1α expression  PGC-1α expression in 
  in blood samples  myocardial biopsy 
     specimens
  >2 fold  <2 fold P >2 fold <2 fold P
Prior diagnosis of diabetes
 Yes 1 8 0.12 1 8 0.19
 No 10 16  9 17 
Prior diagnosis of diabetes and /or glycated hemoglobin of ≥6.5%
 Yes 2 12 0.07 1 13 0.02
 No 9 12  9 12 
Comparisons between groups were made by the chi-square test. Significant if p<0.05
Metabolic disease Present Absent P value 
diabetes and/or (n=14) (n=21)  
Hb1Ac≥6.5%
Peripheral expression (x-fold)
 PGC-1α 1.21 (±2.64) 1.56 (±2.44) 0.68
 SOD2 1.03 (±0.03) 1.20 (±0.43) 0.085
 AMPK 1.06 (±0.06) 1.08 (±0.21) 0.73
 SIRT1 2.75 (±3.95) 3.79 (±4.99) 0.49
 MAP1LC3 1.05 (±0.11) 1.01 (±0.02) 0.11
Myocardial expression (x-fold)
 PGC-1α 1.27 (±0.75) 3.31 (±4.21) 0.043
 SOD2 1.02 (±0.02) 1.55 (±2.39) 0.41
 AMPK 1.02 (±0.01) 1.57 (±1.79) 0.40
 SIRT1 1.03 (±0.04) 1.63 (±2.43) 0.26
 MAP1LC3 1.10 (±0.26) 1.67 (±2.89) 0.47
Total antioxidant status
 Trolox (mM) 0.34 (±0.08) 0.37 (±0.05) 0.34
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Figure 3. Relative mRNA expression of target genes and total 
antioxidant status according to the prevalence of metabolic disorders.
Were considered both known diabetic patients as those with Hb1Ac of ≥6.5%. mRNA 
expression is represented as x -fold expression over the minimum expression detected 
among all patients. SOD2 - superoxide dismutase 2. AMPK-AMP-activated protein kinase. 
SIRT-1 - silent information regulator 2 homolog 1. MAP1LC3 - microtubule-associated 
protein-1 light chain-3. Trolox- 6-hidroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid
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P=0.043
Patients with metabolic 
disorders (n=14)
Patients without metabolic 
disorders (n=21)
Fabregat-Andres et al.
mRNA PGC-1α levels
genesis and antioxidant defenses and an increased reliance on 
oxidative phosphorylation, especially in organs with a high meta-
bolic rate (i.e., brain, muscle, liver, and heart). For example, PGC-
1α plays a key role in regulating the expression of mitochon-
drial antioxidants such as SOD2 in protecting the heart against 
myocardial oxidative stress (23). Furthermore, it is assumed that 
post-transcriptional regulators that enhance PGC-1α activity 
would be upregulated under this condition. In our study, both 
SOD2 and SIRT-1 transcripts tended to be increased in patients 
with a higher PGC-1α expression, although differences were 
not significant in all comparisons. Nonetheless, these results 
together suggest a coordinated activation of the mitochondrial 
protection system regulated by PGC-1α. 
In this regard, when we analyzed the potential link of PGC-
1α mRNA expression with autophagy mechanisms and redox 
status, because these processes have been suggested to be re-
lated in some metabolic stress models (24, 25), we found that the 
upregulation of MAP1LC3 as a marker of autophagy was slight 
and not significant in the group of patients with a higher PGC-
1α expression. However, the estimated antioxidant capacity by 
indirectly Trolox concentration was significantly increased, re-
inforcing the hypothesis of a better redox balance in these pa-
tients. In this respect, several studies have focused on redox ho-
meostasis regulated by PGC-1α and cardioprotection, showing 
that the induction of PGC-1α expression could reduce mitochon-
drial damage (Flameng mitochondrial function score: 0.44±0.13 
in the group with higher expression of PGC-1α vs. 1.70±0.03 in 
the control group) and prevent cellular apoptosis in the remote 
area of the left ventricular myocardium (Connexin 43 expression: 
1.03±0.29 in the group with a higher expression of PGC-1α vs. 
0.53±0.14 in the control group) in acute myocardial infarction 
models (26, 27). Therefore, the clinical use of our protocol to 
monitor PGC-1α expression may be useful in this context.
With regard to immune response analysis, the close relation-
ship between metabolism and immunity and how the aberrant 
expression of PGC-1α could be linked to persistent systemic 
inflammation and a higher risk for some chronic diseases are 
well known (28). Our results indicate a better immune profile in 
patients with a higher PGC-1α expression with less baseline 
CRP levels before surgery and less lactate production at 8 h. 
Furthermore, acute unspecific response represented by neutro-
phil relative change was more tempered in these patients. These 
findings contribute to provide more evidence in recent years 
pointing to a potential link between low-grade inflammation in 
the heart and metabolic dysregulation.
In this respect, novel insights highlight the crosstalk be-
tween inflammatory processes and metabolic alterations in the 
failing heart in diabetic patients (29). Notably, PGC-1α activation 
might prevent metabolic disturbances occurring during diabetic 
cardiomyopathy, while inhibiting inflammatory processes in the 
heart, in particular, modulating nuclear factor-κB. Our previous 
results already indicated that diabetic patients show low PGC-
1α mRNA levels in blood samples, compared with those without 
metabolic disorders. In this study, we proved that the vast major-
ity of known diabetic patients showed lower PGC-1α expression 
both in blood samples and myocardial biopsy specimens, which 
was also observed in patients still not diagnosed with metabolic 
disease but with Hb1Ac of ≥6.5% determined during admission. 
This downregulation of PGC-1α expression was associated by a 
trend to the lower expression of different gene targets analyzed 
and the antioxidant status of patients.
Study limitations
There are some limitations such as the small sample size of 
patients, single-center experience, and unique blood samples 
and myocardial biopsy specimens for each patient. Nonethe-
less, although some results did not reach statistical significance, 
they are consistent with those found in our previous studies. 
Conclusions
In this study performed in patients undergoing cardiac sur-
gery, mRNA PGC-1α expression in blood samples showed a good 
correlation with the expression in myocardial biopsy specimens. 
The presence of a higher systemic PGC-1α expression was as-
sociated with higher peripheral SIRT-1 levels and Trolox concen-
tration, suggesting a better antioxidant status in these patients. 
Conversely, lower PGC-1α levels were related to a significant 
inflammation profile, and this condition was more frequent in 
patients with metabolic disorders.
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